Curia Global Holdings Ltd.

Board will help advance the mission and support development of our game-changing IUD for contraception (3D-001)MANSFIELD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- 3Daughters, a clinical development company fueling evolutionary healthcare for women, announced the appointment of Michele LaRussa, Vincent J. Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors. These strategic appointments mark a significant milestone in the company's plan to revolutionize birth control with a newly designed Intrauterine Device (IUD), 3D-001, to address a major barrier to adoption, insertion pain. An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial. Ms. LaRussa, Dr. Miles, and Dr. Stevens provide a collective wealth of experience and skillful expertise from the life sciences industry, perfectly aligning with 3Daughters' mission to drive therapeutic innovation within the women's health arena. Their appointments are set to enhance the company's strategic direction and drive the development of groundbreaking healthcare solutions for women, starting with the revolutionary frameless, magnetic nonhormonal IUD. Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors. Their invaluable experience with the crucial aspects of an emerging life sciences company - regulatory affairs, drug development, manufacturing, and fundraising, are exactly what 3Daughters needs as we move into the clinic with our novel IUD and Slider™ system (inserter/retriever) to address insertion pain, a major barrier to adoption. Their guidance and enthusiasm will be instrumental in shaping a future where women will have improved healthcare options." Ms. LaRussa has a distinguished career in regulatory affairs and clinical development, built over 32 years of experience in various therapeutic areas. Currently, she is the Chief Regulatory Officer at SFJ Pharmaceuticals, following a significant 13-year tenure at Novartis, where she held leadership roles, including Chief of Staff to the Global Head of R&D. Her extensive background includes key positions at Allergan, GlaxoSmithKline, Kala Pharmaceuticals, and Liquidia Technologies, and she was the Chief Regulatory Officer at Atox Bio. Michele has a B.Sc. in Chemistry degree from the University of South Florida. Dr. Miles is a well-known and respected member of the biotech and venture capital community with a career spanning more than 45 years that encapsulates a spectrum of pivotal roles that have influenced the industry's growth. For the last 16 years, Vin has been a partner and executive director at Abingworth, a key life sciences investment firm, and has served on the boards of multiple biotech companies, including IFM Therapeutics, Dicerna Pharmaceuticals, Chiasma, Hydra Biosciences, and Personalis. His previous roles include Senior Vice President at Alnylam Pharmaceuticals and VP positions at Millennium Pharmaceuticals, RiboGene, and Pharmacia. He also directed the technology transfer office at Dana-Farber Cancer Institute and started his career in R&D at Amersham International. Dr. Miles holds a B.Sc. in Biochemistry and a Ph.D. in Biochemical Embryology from University College London. Dr. Stevens, with over 20 years in the biopharmaceutical industry, currently leads the Labs & Cleanroom on Demand Business Unit at Azzur Group, delivering bespoke solutions to early-phase manufacturers for faster market entry. Her career spans pivotal roles in CDMO and CRO leadership, including Senior Vice President at Quotient Sciences and Global Head of Drug Product Development at Albany Molecular Research. Sarah has a rich background in drug development and manufacturing and contributed to novel drug formulations at Encap Drug Delivery with patented oral dosage forms during her post-doctoral fellowship at the University of Strathclyde. Her academic credentials include an M.Pharm and an MBA from the University of Strathclyde, a Ph.D. in Pharmaceutical Sciences from the University of Manchester, and a Lean Six Sigma Green Belt. Michele, Vin and Sarah’s expertise and experience will significantly contribute to the company's aggressive plans for clinical development of a game-changing IUD for contraception. With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare. About 3Daughters™ 3Daughters is a clinical development company focused on evolutionary healthcare for women where cutting-edge research and innovation is desperately needed. The Company’s technology platform is based on physics and geometry to deliver targeted therapy to the uterus. The first product, (3D-001), is a frameless, magnetic, nonhormonal intrauterine device (IUD) for long-acting contraception that conforms to a woman’s body and is combined with our unique, patented Slider™ system (insertion/ retrieval) designed to eliminate steps and pain points as well as the nuisance factor of strings (needed for removal). 3Daughters’ vision is to solve health issues for women, particularly significant (neglected) problems. 3Daughters plans to radically disrupt the IUD market by addressing the major adoption barrier — insertion pain. This pain is associated with all current rigid, plastic T-shape framed IUDs on the market and prevents women from selecting one of the most effective forms of birth control. Visit 3daughtershealth.com for more information. Contact: Louis Scottiinfo@3Daughtershealth.com

DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Genomics Partnering Terms and Agreements 2016 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Genomics Partnering Terms and Agreements 2016 to 2023 report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies. Trends in genomics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Genomics partnering contract documents Top genomics deals by value The Global Genomics Partnering Terms and Agreements report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in genomics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading genomics deals since 2016. Deals are listed by headline value, signed by big pharma, most active genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomics dealmaking with a brief summary followed by a comprehensive listing of genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by genomics partnering company A-Z, deal type definitions and genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in genomics partnering and dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genomics technologies and products. Report scope Global Genomics Partnering Terms and Agreements 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to genomics trends and structure of deals entered into by leading companies worldwide. Global Genomics Partnering Terms and Agreements 2016 to 2023 includes: Trends in genomics dealmaking in the biopharma industry since 2016 Access to headline, upfront, milestone and royalty data Access to over 800 genomics deal records and contract documents where available The leading genomics deals by value since 2016 Most active genomics dealmakers since 2016 The leading genomics partnering resources In Global Genomics Partnering Terms and Agreements 2016 to 2023, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in genomics dealmaking 2.1. Introduction 2.2. Genomics partnering over the years 2.3. Most active genomics dealmakers 2.4. Genomics partnering by deal type 2.5. Genomics partnering by therapy area 2.6. Deal terms for genomics partnering 2.6.1 Genomics partnering headline values 2.6.2 Genomics deal upfront payments 2.6.3 Genomics deal milestone payments 2.6.4 Genomics royalty rates Chapter 3 - Leading genomics deals 3.1. Introduction 3.2. Top genomics deals by value Chapter 4 - Most active genomics dealmakers 4.1. Introduction 4.2. Most active genomics dealmakers 4.3. Most active genomics partnering company profiles Chapter 5 - Genomics contracts dealmaking directory 5.1. Introduction 5.2. Genomics contracts dealmaking directory Chapter 6 - Genomics dealmaking by technology type Companies Mentioned 1CellBiO 2bPrecise 2seventy bio 3 Sisters Surrogacy 3D Signatures 4baseCare 10X Genomics 14M Genomics 22nd Century 23andMe A*STAR Agency for Science Technology and Research A*STAR Bioinformatics Institute A*STAR Genome Institute of Singapore Abbvie Abcam Abramson Cancer Center Absorption Systems Academia Sinica Accelerated Cure Project for MS Accelerate Technologies Access to Comprehensive Genomic Profiling Coalition Acerta Pharma ACMG Foundation for Genetic and Genomic Medicine ACT Genomics Active Motif ActX Adaptimmune Adaptive Biotechnologies ADInstruments Admera Health Adrestia Advaita ADx Healthcare Aelan Cell Technologies Aevi Genomic Medicine Affymetrix AgBiome Agendia Agilent Technologies Agribody Technologies Agriplex Genomics AiLife Diagnostics Aitbiotech Akadeum Life Sciences AKESOgen Alana Healthcare Albany Molecular Research Alexion Pharmaceuticals AllCells Allele Biotechnology and Pharmaceuticals Almac Diagnostics Alnylam Pharmaceuticals ALS Association ALS Automated Lab Solutions Altor BioScience Alzheimer's Drug Discovery Foundation Amazon Web Services Ambry Genetics America's Choice Provider Network American Physiological Society American Society of Clinical Oncology (ASCO) American Type Culture Collection (ATCC) Amgen Amplicon Express Analytical BioSciences Anam Hospital Angsana Molecular & Diagnostics AnimalBiome Annoroad APG Bio Applied Biosystems Aptorum Group Arbor Biotechnologies Arcadia Biosciences Arc Bio ArcherDX Arcturus Therapeutics Argonaut Arima Genomics Arzeda Aslan Pharma Astellas Pharma AstraZeneca Astrea Forensics Athletigen Atlas Genetics Atlas Genomics ATUM Auria Biobank Avance Biosciences Avera Health Avera Heart Hospital of South Dakota Avvinity Therapeutics Axil Scientific B-MoGen Biotechnologies Baheal Pharmaceutical Bank of America Banner Health BASF Battelle Bayer Bayer CropScience Bayer Healthcare Baylor College of Medicine Baylor Genetics Baylor Miraca Genetics Laboratories BC Platforms BD Biosciences Beckman Coulter Becton Dickinson Beijing Genomics Institute (BGI) Beijing InnoCare Pharma Belgian Society of Medical Oncology Benson Hill Biosystems Berkeley Lights Berry Genomics Beth Israel Deaconess Medical Center BGI BGI Americas Bill and Melinda Gates Foundation Bina Technologies Bio-Rad Laboratories Bio-Techne BioBright Biocartis Biocept Biodesix BioDiscovery BioFire Diagnostics Biogen BioIntelliSense BioIQ BioLegend BioMap BioMarin Pharmaceutical Biomecite Diagnostics Biomedical Advanced Research and Development Authority BioMed X Innovation Center Biomillenia BioNano Genomics BioNova Cientifica BioReference Laboratories BioSkryb Biosplice Biostar BioTheranostics Biotop Blackfynn Blockchain Global Bluebird Bio Blue Cross Blue Shield Association For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

GTCR announced that it entered into a Leaders Strategy partnership to form Epselon Global to acquire healthcare businesses. The private equity firm partnered with Michael Mulhern and Phil Macnabb to form the Chicago-based company centered around acquiring companies and assets as part of a strategy to build a market-leading healthcare business, according to a news release. Leaders Strategy was pioneered by GTCR to find and partner with management leaders in core domains to identify, acquire and build market-leading companies. Through the Leaders Strategy, GTCR will invest in Epselon from its GTCR Fund XIII, a private equity fund with $7.5 billion in limited partner capital commitments. Mulhern will serve as the executive chairman and Macnabb will hold the role of CEO, while each will make a substantial investment alongside GTCR. “We are very excited to once again partner with Michael and Phil,” GTCR managing director Sean Cunningham said in the release. “As a result of our long-term relationship and previous partnerships with them, we have tremendous respect for their strategic vision, operational abilities and M&A acumen. Their broad industry experience and expertise within healthcare make them ideal partners as GTCR commits to building another platform in the space.” Mulhern has previously been CEO of four companies — Sotera Health, Albany Molecular Research, Fairmount Food Group and American Sanitary — all backed by GTCR. He also held other roles at Baxter and Alliant Foodservice. Macnabb worked with Mulhern at Sotera Health, Fairmount Food Group and American Sanitary. He most recently served as president of Sotera Health’s largest division, Sterigenics. “I am thrilled about the opportunity to work with GTCR for a fifth time and to build a leading healthcare company as part of The Leaders Strategy,” added Mulhern. “GTCR has been an ideal partner over the past two decades, demonstrating exceptional leadership, enabling growth and providing the support and resources required to build successful companies. I look forward to this next partnership with GTCR and Phil.” “It is a great opportunity to once again partner with GTCR,” Macnabb said. “The support and domain expertise provided by GTCR has been instrumental in the success of our past partnerships. GTCR focuses on building real and sustained value in the companies they invest in. With Epselon Global, we plan to invest in the healthcare sector at a time of rapid change and, together with Michael and GTCR, I believe we can create something unique with a lasting positive impact in the industry.”